2018 Press Releases

»2018 Press Releases
19 12, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies

2018-12-19T14:26:30+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies Survival Benefit in Children with Progeria Published in JAMA 2018 NDA Filing Planned in 2019 PALO ALTO, Calif., December 19, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies2018-12-19T14:26:30+00:00
18 12, 2018

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection

2018-12-18T15:15:54+00:00

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection Phase 3 HDV “D-LIVR” International Study Initiating PALO ALTO, Calif., December 18, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European [...]

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection2018-12-18T15:15:54+00:00
17 12, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection

2018-12-17T17:00:35+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection - Phase 3 HDV “D-LIVR” International Study Initiating PALO ALTO, Calif., December 17, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection2018-12-17T17:00:35+00:00
11 12, 2018

Eiger BioPharmaceuticals Reports on 2018 R&D Day

2018-12-11T21:30:44+00:00

Eiger BioPharmaceuticals Reports on 2018 R&D Day Late Stage Rare and Ultra-Rare Disease Pipeline Advancing >$100M in Cash Available to Achieve Key Milestones PALO ALTO, Calif., December 11, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced recent accomplishments reported at [...]

Eiger BioPharmaceuticals Reports on 2018 R&D Day2018-12-11T21:30:44+00:00
4 12, 2018

Eiger BioPharmaceuticals to Host R&D Day in New York City

2018-12-04T14:51:54+00:00

Eiger BioPharmaceuticals to Host R&D Day in New York City PALO ALTO, Calif., December 4, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at [...]

Eiger BioPharmaceuticals to Host R&D Day in New York City2018-12-04T14:51:54+00:00
3 12, 2018

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies

2018-12-03T15:51:26+00:00

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies Plans to File NDA in 2019PALO ALTO, Calif., December 3, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the U.S. Food and [...]

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies2018-12-03T15:51:26+00:00
3 12, 2018

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer

2018-12-04T11:27:49+00:00

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer PALO ALTO, Calif., December 3, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as the company’s Chief Financial Officer.  Mr. Ryali brings over fifteen [...]

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer2018-12-04T11:27:49+00:00
19 11, 2018

Eiger to Participate in Piper Jaffray Healthcare Conference

2018-11-21T11:28:38+00:00

Eiger to Participate in Piper Jaffray Healthcare Conference PALO ALTO, Calif., November 19, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 [...]

Eiger to Participate in Piper Jaffray Healthcare Conference2018-11-21T11:28:38+00:00
9 11, 2018

Eiger Bio Reports Third Quarter 2018 Financial Results

2018-11-09T14:32:39+00:00

Eiger Bio Reports Third Quarter 2018 Financial Results - HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 - Over $100 million in cash to advance late stage rare disease pipeline PALO ALTO, Calif., November 9, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger Bio Reports Third Quarter 2018 Financial Results2018-11-09T14:32:39+00:00
23 10, 2018

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

2018-11-07T11:44:18+00:00

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PALO ALTO, Calif., October 23, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced [...]

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock2018-11-07T11:44:18+00:00